Projects funded by the NCN
Liposomal nanoformulations of cannabidiol with celecoxib or 2,5-dimethylcelecoxib as a novel treatment option for glioblastoma multiforme
2021/43/O/NZ5/02346
Keywords:
Cannabidiol Celecoxib 2,5- Dimethylcelecoxib NF-kB Nrf2 Wnt glioblastoma multiforme
Descriptors:
- NZ5_3: Pathogenesis of human diseases
- NZ5_7: Human disease treatment
Panel:
NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution :
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
woj.
Principal investigator (from the host institution):
dr hab. Violetta Katarzyna Krajka-Kuźniak
Number of co-investigators in the project: 2
Call: PRELUDIUM BIS 3 - announced on 2021-09-15
Amount awarded: 602 490 PLN
Project start date (Y-m-d): 2022-10-01
Project end date (Y-m-d): 2025-09-30
Project duration:: 36 months (the same as in the proposal)
Project status: Pending project
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (2)
- Targeting Nrf2 Signaling Pathway in Cancer Prevention and Treatment: The Role of Cannabis CompoundsAuthors:Rybarczyk, A.; Majchrzak-Celińska, A.; Krajka-Kuźniak, V.Academic press:Antioxidants (rok: 2023, tom: 12, strony: 45677), Wydawca: MDPIStatus:PublishedDOI:10.3390/antiox12122052 - link to the publication
- The application of cannabidiol in the treatment of glioblastomaAuthors:Rybarczyk, A.; Majchrzak-Celińska, A.; Krajka-Kuźniak, VAcademic press:Acta Poloniae Pharmaceutica -Drug Research (rok: 2023, tom: 80, strony: 207-217), Wydawca: Polskie Towarzystwo FarmaceutyczneStatus:PublishedDOI:10.32383/appdr/163414 - link to the publication